Saghmos Therapeutics, INC.
Bio-pharmaceutical company
Based in CT
AI Overview
With $280K in lobbying spend across 11 quarterly filings, Saghmos Therapeutics, INC is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2020 to 2022.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $150K |
| 2021 | $130K |
| 2022 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Saghmos Therapeutics, INC. disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid
induced acute kidney injury
Prevention of contrast-induced acute kidney injury and major adverse renal and cardiac events after percutaneous coronary intervention.
Issues related to the policies proposed in the 21st Century Cures 2.0 Concept Paper. Education; and awareness, generally, regarding treatment of contrast-induced acute kidney injury after percutaneous
Medicare beneficiary access to a potential treatment to prevent contrast-induced acute kidney injury and major adverse renal and cardiac events after percutaneous coronary intervention, as well as pot
Issues related to the policies proposed in the 21st Century Cures 2.0 Concept Paper. Education and awareness, generally, regarding treatment of contrast-induced acute kidney injury after percutaneous
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.